Urtė Fultinavičiūtė

The fight between Teva and Amneal over the ProAir HFA inhaler has reached another milestone, with the appellate court affirming the previous ruling to delist five patents from the FDA’s Orange Book. However, Teva might not be backing down.

Celebrating its first birthday as a transformed and integrated company, Biocon casts a wider net for its ustekinumab biosimilar.

In an exclusive interview with Generics Bulletin, Aspargo Labs CEO Michael Demurjian discusses the importance of reformulated liquid oral suspension drugs, while outlining plans to launch a smart device that connects patients and doctors.

At the 2025 J.P. Morgan Healthcare Conference, Johnson & Johnson outlined a new competition blueprint for anti-inflammatory biosimilars, going beyond the next blockbuster Tremfya.

While Amneal cannot wait to jump into unexplored biologics space, it wants to channel its GLP-1 power into the Metsera partnership and service big pharma, and less so on its own generics.

Henlius casts a wider net for its biosimilars presence by locking in a fresh deal with the already-established partner Abbott. Also, the Chinese biosimilars developer has joined the Biosimilars Forum, securing its footing in the US.

CEO Michael Demurjian discusses the importance of reformulated liquid oral suspension drugs, while outlining plans to launch a smart device that connects patients and doctors.

Generics Bulletin reviews global regulatory developments from late 2024 and new updates from this year.

The Teva v. Amneal battle over inhaler patents in the FDA's Orange Book has become a noteworthy case that will impact both branded and generic drug companies. Yet, the clarity over patent listings might be overshadowed by possible future litigations, discussed law firm Polsinelli's chair Chad Landmon with Generics Bulletin.

Amneal builds on its affordable medicines business with three FDA approvals – two final and one tentative – for generic rivals referencing AbbVie's Namzaric, Novartis' Afinitor Disperz, and Bausch Health's Xifaxan.